Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitorsMaryam Ahmadi(University of Bradford), Roger M. Phillips(University of Bradford)British Journal of PharmacologyOctober 12, 201310.1111/bph.12438Cited by 33SaveCiteExport RISWatch citationsRelated PapersIdentification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways|Oncogenesis|2014|142Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands|Cancer Letters|2017|67